10.09.20
Gencor, a global botanical ingredients supplier, recently launched a water-dispersible resveratrol powder called Veri-Sperse, featuring Veri-te, a clinically studied resveratrol extract developed by Evolva, combined with the company’s own LipiSperse liquid dispersion technology. Veri-te has been the featured ingredient in two recently-published clinical trials in the Journal of North American Menopause Society, which found that supplementation resulted in reduced pain perception, menopausal symptoms, and overall well-being, and the journal Clinical Nutrition, which found that long-term supplementation improved bone mineral density in postmenopausal women.
LipiSperse technology improves the bioavailability of resveratrol by two- or threefold, Gencor reports. The technology increases the active loads and improves the functionality of the ingredient in beverages, and the bioavailability increases through VeriSperse have been clinically validated by a human pharmokinetic study, Gencor reports. It works by creating a repulsion between the powder surface of VeriSperse and a solution to establish an equilibrium, preventing particle agglomeration or aggregation, thus allowing the resveratrol to easily disperse in water.
“Given Veri-Te’s recently published clinical outcomes by The Journal of North American Menopause Society and Clinical Nutrition, we feel even more confident in the ability of the resveratrol to address critical life markers and symptoms for menopausal women,” Case Shyroc, vice president of Sales and Business Development for Gencor, said. “In marrying Veri-te and LipiSperse technologies, Veri-Sperse Resveratrol provides a superior resveratrol that can be applied in limitless applications to support healthy aging and improved quality of life for women suffering the symptoms of menopause.”
Veri-te resveratrol was the focal point of RESHAW, a large-scale, peer-reviewed research project which studied the potential cognitive benefits of resveratrol in 125 postmenopausal women over a period of 2 years. It found that women who took 75 mg of resveratrol twice daily had a 33% improvement in cognitive battery tests, and women 65 years and older shoed a 76% improvement on verbal memory assessments.
LipiSperse technology improves the bioavailability of resveratrol by two- or threefold, Gencor reports. The technology increases the active loads and improves the functionality of the ingredient in beverages, and the bioavailability increases through VeriSperse have been clinically validated by a human pharmokinetic study, Gencor reports. It works by creating a repulsion between the powder surface of VeriSperse and a solution to establish an equilibrium, preventing particle agglomeration or aggregation, thus allowing the resveratrol to easily disperse in water.
“Given Veri-Te’s recently published clinical outcomes by The Journal of North American Menopause Society and Clinical Nutrition, we feel even more confident in the ability of the resveratrol to address critical life markers and symptoms for menopausal women,” Case Shyroc, vice president of Sales and Business Development for Gencor, said. “In marrying Veri-te and LipiSperse technologies, Veri-Sperse Resveratrol provides a superior resveratrol that can be applied in limitless applications to support healthy aging and improved quality of life for women suffering the symptoms of menopause.”
Veri-te resveratrol was the focal point of RESHAW, a large-scale, peer-reviewed research project which studied the potential cognitive benefits of resveratrol in 125 postmenopausal women over a period of 2 years. It found that women who took 75 mg of resveratrol twice daily had a 33% improvement in cognitive battery tests, and women 65 years and older shoed a 76% improvement on verbal memory assessments.
